Ryan Kruger, PhD
Ryan Kruger, PhD, joined Foghorn Therapeutics in March 2021 as VP of Biology. He brings more than 16 years of experience in the field of epigenetics research.
Prior to joining Foghorn, Ryan was the VP, Head of Cancer Epigenetics Research at GlaxoSmithKline (GSK). In this position, he established the strategy for the Epigenetics unit that focused on identifying targets and progressing evidence-based candidates for their role in cancer with genetic/epigenetic biomarkers. Notably, Ryan also served as the Early Development Leader for one of GSK’s compounds and led the clinical team in three tumor types from first in human trial through combination studies in the clinic.
Ryan received his bachelor’s degree in Biochemistry from Rensselaer Polytechnic Institute and his PhD from the University of Pennsylvania. He completed his post-doctoral training with Christopher T. Walsh at Harvard Medical School. During his career, Ryan has authored or coauthored 48 publications and has received numerous awards and fellowships.